Sanofi-Aventis SA (ADR) 

(Public, NYSE:SNY)   Watch this stock   
Find more results for SNY
Feb 10, 2010
Q4 2009 Earnings Release - 6:00AM EST - Add to calendar
Jan 12, 2010
JPMorgan Healthcare Conference - 3:00PM EST - Add to calendar
Dec 17, 2009
Investors Seminar on Vaccines - 8:00AM EST - Add to calendar
Oct 30, 2009
Q3 2009 Earnings Conference Call
Oct 30, 2009
Q3 2009 Earnings Release
Sep 15, 2009
Morgan Stanley Healthcare Conference
Sep 15, 2009
Merrill Lynch/Bank of America Global Drug, Biotech & Medical Devices Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 16.13% 12.08%
Operating margin 22.58% 15.25%
EBITD margin - 30.26%
Return on average assets - 4.84%
Return on average equity - 8.61%
Employees 98,213 -

Address

174 avenue de France cedex 13
Paris, 75635
France
+33-1-53774000 (Phone)
+33-1-53774296 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Sanofi-Aventis SA (ADR) discussed on blogs

Ranking Healthcare Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 19, 2009
First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm ... - Recordaf Registry - PR Hub - Nov 15, 2009
Why Did Buffett Buy Glaxo SmithKline and Kraft? -- Seeking Alpha - Dickie Paria - SeekingAlpha.com: Home Page - Apr 10, 2008

Sanofi-Aventis SA (ADR) discussions

  View all discussions »

Description

Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company's business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. In its pharmaceutical activity, Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. On September 1, 2008, Sanofi-Aventis acquired the Australian company, Symbion CP Holdings Pty Ltd (Symbion Consumer). On September 25, 2008, it acquired Acambis plc. In January 2009, the Company sold its French plant of Colomiers to French pharmaceutical company Unither. In April 2009, the Company acquired Mexican generic company, Laboratorios Kendrick.

Officers and directors

Jean-Francois Dehecq
Chairman of the Board
Age: 69
Bio & Compensation - Reuters
Christopher Viehbacher
Managing Director (CEO), Member of the Executive Committee, Director
Age: 48
Bio & Compensation - Reuters
Jerome Contamine
Chief Financial Officer
Age: 51
Bio & Compensation - Reuters
Christian Lajoux
President - Sanofi-Aventis in France
Portrait. Bio & Compensation - Reuters
Hanspeter Spek
President - Global Operations, Member of the Executive Committe
Age: 59
Bio & Compensation - Reuters
Marc Cluzel
Executive Vice President - Research & Development, Member of the Executive Committee
Bio & Compensation - Reuters
Philippe Fauchet
Senior Vice President, Vice President - Business Development
Portrait. Age: 49
Bio & Compensation - Reuters
Karen Linehan
Senior Vice President - Legal Affairs and General Counsel, Member of the Executive Committee
Age: 50
Bio & Compensation - Reuters
Jean-Francois Brin
Senior Vice President - Global Marketing and Access
Bio & Compensation - Reuters
Roberto Pucci
Senior Vice President - Human Resources, Member of the Executive Committee
Age: 45
Bio & Compensation - Reuters